Company profile for Vandria

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vandria SA, established as a biopharmaceutical spin-off from Amazentis SA, was officially incorporated in Switzerland in 2021. The company specializes in the discovery and development of innovative small molecules designed to effectively induce mitophagy for the treatment of age-related and chronic diseases. Vandria is currently in the IND-enabling stage, boasting two lead candidates who have demonstrated highly promising resu...
Vandria SA, established as a biopharmaceutical spin-off from Amazentis SA, was officially incorporated in Switzerland in 2021. The company specializes in the discovery and development of innovative small molecules designed to effectively induce mitophagy for the treatment of age-related and chronic diseases. Vandria is currently in the IND-enabling stage, boasting two lead candidates who have demonstrated highly promising results in both in vitro and in vivo studies. Anticipated to commence in the second quarter of 2024, the first clinical trials mark a significant milestone.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Route de la Corniche 8, 1066 Epalinges , Switzerland
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/12/18/2998783/0/en/Vandria-announces-first-subjects-dosed-in-its-first-in-human-Phase-1-clinical-trial-of-VNA-318-brain-penetrant-mitophagy-inducer.html

GLOBENEWSWIRE
18 Dec 2024

https://www.globenewswire.com/news-release/2024/08/21/2933277/0/en/Hevolution-Foundation-and-Dolby-Family-Ventures-join-Vandria-s-2nd-Series-A-closing-bringing-the-total-round-to-30-7M-CHF-28-3M-to-Progress-the-Mitophagy-Inducer-VNA-318-into-CNS-C.html

GLOBENEWSWIRE
21 Aug 2024

https://www.globenewswire.com//news-release/2024/02/08/2825744/0/en/Vandria-Awarded-3-8M-in-Prestigious-Innosuisse-and-Eurostars-Grants-to-Advance-Innovative-Drug-Programs-for-Age-Related-Diseases-of-the-CNS-and-Muscle.html

GLOBENEWSWIRE
08 Feb 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty